Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2026

Conditions
Follicular Lymphoma
Interventions
BIOLOGICAL

Oncoquest-L vaccine

Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.

Trial Locations (1)

30265

Southeastern Regional Medical Center at CTCA, Newnan

All Listed Sponsors
lead

XEME Biopharma Inc.

INDUSTRY